MedComm · Nov 13, 2026

Metformin Promotes Cholangiocyte Regeneration in Cholestatic Fibrosis via HK1‐Glycolysis‐Dependent Epigenetic Activation of LGR5

By Liang Y, Ye Y, Lian H et al.

Cholestatic liver fibrosis, characterized by impaired cholangiocyte regeneration and elevated epithelial–mesenchymal transition (EMT)‐like remodeling, lacks effective therapeutic treatment options. Although drug repurposing was explored, metformin was identified as a potential therapeutic candidate for cholestasis, as it is a safe and cost‐effective agent with established hepatic bioavailability. Using bile duct ligation and Mdr2 −/− mouse models, we demonstrated metformin promoted cholangiocyte regeneration and attenuated EMT‐like remodeling. Transcriptomic analysis identified HK1‐mediated glycolysis as a key downstream pathway upregulated by metformin. Cholangiocyte‐specific Hk1 conditional knockout mice demonstrated that HK1 is essential for the antifibrotic and regenerative effects of metformin on cholangiocytes. Mechanistically, metformin enhanced HK1‐mediated glycolysis in cholangiocyte organoids, increasing acetyl‐CoA and H4K16ac enrichment at the Lgr5 promoter, thereby promoting Lgr5 transcription and expression. Inhibition of ACLY activity or H4K16ac deposition abolished metformin‐induced LGR5 upregulation and organoid regeneration, indicating H4K16ac is functionally required for Lgr5 transcription and the associated regenerative response. These findings were corroborated in organoids derived from biliary atresia patients. Collectively, our findings demonstrated metformin activates the HK1–glycolysis–acetyl‐CoA–H4K16ac–LGR5 axis to promote cholangiocyte regeneration. Given its established safety profile and cost‐effectiveness, metformin represents a promising candidate for further preclinical and translational investigation as a therapeutic strategy for cholestasis.

doi.org/10.1002/mco2.71143Open accessPubMed 43032636Interventions

AgingResearch.News